Physician profile
Hatem Asad
NPI 1326095662
$11,979.30
in general payments reported to CMS, 2019-2025
45 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $1,390 · 2021: $1,299 · 2022: $1,993 · 2023: $1,751 · 2024: $3,044 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642 · Education: $1,547 · Travel and Lodging: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.99 |
| Education | $1,546.99 |
| Travel and Lodging | $456.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,473.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Intuitive Surgical, INC. | $2,043.33 | 2024 | |
| Harmony Biosciences LLC | $1,289.03 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $1,121.04 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Mylan Specialty L.P. | $562.17 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.30 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Grifols USA, LLC | $477.00 | 2019-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $411.69 | 2020-2024 | Glassia |
| Insmed, INC. | $289.05 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $274.90 | 2019-2023 | Opsumit |
| Jazz Pharmaceuticals INC. | $240.35 | 2019-2025 | |
| Baxter Healthcare | $226.72 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $186.95 | 2019-2021 | |
| United Therapeutics Corporation | $175.57 | 2019-2023 | Tyvaso |
| Ani Pharmaceuticals, INC. | $154.24 | 2023-2025 | Purified Cortrophin Gel |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hatem Asad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.